VIVA
维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
股票代號:1873

Issue 19
NEWSLETTER
September – December 2024

Highlights

I. Business Progress

- Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
- Completion of Joint-stock Conversion of Viva Shanghai
- Viva Biotech's "She Power" Featured in JCIM, Demonstrating the Charm of Female Scientists on Viva's CADD and AIDD Platform
- Nature Oncogene Publishes Study Highlighting TMBIM6's Transformative Potential in Treating Cancer and Beyond—Viva Biotech's AIDD/CADD Platform Made Key Contributions to the Novel Scientific Discovery
- Science Advances Published A New Study: Structural Biology Reveals the Regulatory Mechanisms of PLCγ2 —Viva Biotech's Protein Structure Research Team Make a Key Contribution

II. Portfolio Companies' Project Progress

- TJ Biopharma and Jumpcan Pharmaceutical Jointly Announced that the Marketing Application for Long-acting Eftansomatropin Alfa has been Accepted, and Reached a Strategic Cooperation in Greater China on Global Innovative CD73-targeted Tumor Therapies with Sanofi
- Antag Therapeutics Announces €80 Million Series A Financing and FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687
- VivaVision Biotech reports positive Ph2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery
- Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes
- Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
- HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform

Business Progress

Viva Biotech Officially Establishes Boston Branch Marking Another Milestone in Global Expansion

Viva Biotech announced the official establishment of its new branch in Boston, USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the company's global expansion strategy. Viva Biotech aims to further enhance and deepen international collaboration networks, providing comprehensive one-stop CRO-CMC/CDMO services—from drug discovery and preclinical development to commercial manufacturing—for clients worldwide.

Completion of Joint-stock Conversion of Viva Shanghai

On September 27, 2024, Viva Biotech (Shanghai) Ltd. (維亞生物科技(上海)有限公司, "Viva Shanghai"), a limited liability company established in the PRC and an indirect non-wholly owned subsidiary of Viva Biotech has completed the registration procedures with the State Administration for Market Regulation for its conversion into a joint-stock company with limited liability on September 26, 2024. Immediately upon completion of the joint-stock company conversion, Viva Shanghai will have a issued share capital of RMB446,018,390, and Viva Biotech is indirectly interested in RMB325,179,147 of its issued share capital, representing approximately 72.9071% of its entire issued share capital.

Viva Biotech's "She Power" Featured in JCIM, Demonstrating the Charm of Female Scientists on Viva's CADD and AIDD Platform

Viva Biotech published a perspective titled "Breaking the Gender Imbalance: Female Presence in the Computational Chemistry Group at Viva Biotech" on the Journal of Chemical Information and Modeling (JCIM) of the American Chemical Society (ACS). Dr. Yue Qian, the Executive Director of Computational Chemistry and Artificial Intelligence for Drug Discovery (CADD and AIDD) Platform at Viva Biotech, is the first author. In this article, she highlighted the growing importance of computational chemistry and AI in drug discovery and the significant contributions made by female scientists in this field. The article shares personal experiences and explores how female scientists can effectively increase their visibility and impacts at work, encouraging more women to engage in careers they are passionate about.

Business Progress

Nature Oncogene Publishes Study Highlighting TMBIM6's Transformative Potential in Treating Cancer and Beyond—Viva Biotech's AIDD/CADD Platform Made Key Contributions to the Novel Scientific Discovery

Viva Biotech announced the official establishment of its new branch in Boston, USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the company's global expansion strategy. Viva Biotech aims to further enhance and deepen international collaboration networks, providing comprehensive one-stop CRO-CMC/CDMO services—from drug discovery and preclinical development to commercial manufacturing—for clients worldwide.

Science Advances Published A New Study: Structural Biology Reveals the Regulatory Mechanisms of PLCγ2 —Viva Biotech's Protein Structure Research Team Make a Key Contribution

On November 29, 2024, the journal Science Advances published a research paper titled "The crystal and cryo-EM structures of PLCγ2 reveal dynamic interdomain recognitions in autoinhibition" offering exciting progress in addressing this scientific mystery. This study was co-conducted by a research team led by Dr. Dongming Qian, Vice President of Protein and Structural Biology at Viva Biotech. Leveraging the company's state-of-the-art protein structure elucidation platform, the team provided critical support for uncovering the molecular regulatory mechanisms of PLCγ2.

Portfolio Companies' Project Progress

TJ Biopharma and Jumpcan Pharmaceutical Jointly Announced that the Marketing Application for Long-acting Eftansomatropin Alfa has been Accepted, and Reached a Strategic Cooperation in Greater China on Global Innovative CD73-targeted Tumor Therapies with Sanofi

On December 9, 2024, TJ Biopharma, a full industry chain biotech company focusing on the development, manufacturing and collaborative commercialization of innovative biologics in the fields of autoimmune diseases and oncology, in which Viva BioInnovator (VBI) has invested, jointly announced with Jumpcan Pharmaceutical Group Co., Ltd. ("Jumpcan Pharmaceutical") that the Biologics License Application (BLA) for long-acting recombinant human growth hormone injection, eftansomatropin alfa ("Long-acting Eftansomatropin Alfa") for the treatment of pediatric growth hormone deficiency (PGHD) has been accepted by the National Medical Products Administration (NMPA). As the first and only long-acting growth hormone with fusion protein in the domestic application phase and among marketed products, the innovative therapy is expected to provide a safe, effective and more convenient treatment option for patients with PGHD.

天境生物 TJ BIOPHARMA

Previously, on September 25, 2024, TJ Biopharma has reached a strategic cooperation with Sanofi on the development, production and commercialization of the globally innovative CD73 antibody uliledlimab independently developed by TJ Biopharma in Greater China. This strategic cooperation fully combines TJ Biopharma's excellent R&D and production capabilities in the field of innovative drugs with Sanofi's mature commercial network and channel advantages in the Chinese market, aiming to bring more breakthrough treatments to cancer patients and meet clinical needs that are currently not fully met.

VIVA Linkedin

Portfolio Companies' Project Progress

Antag Therapeutics Announces €80 Million Series A Financing and FDA Clearance of Investigational New Drug (IND) Application for Lead Molecule, AT-7687

Antag Therapeutics, a next-generation biopharmaceutical company which is invested and incubated by Viva BioInnovator (VBI) pioneering novel treatments for obesity, announced the closing of an €80 million Series A financing. The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of Denmark (EIFO).

Previously on October 9, 2024, Antag announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for its lead molecule, AT-7687. This milestone enables Antag Therapeutics to initiate its Phase I clinical trial, which will evaluate the safety, tolerability, and pharmacokinetics of AT-7687 in both healthy lean and healthy obese subjects. The study will also explore AT-7687 as a monotherapy and in combination with semaglutide, a GLP-1 receptor agonist, in healthy obese individuals.

VivaVision Biotech reports positive Ph2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery

VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company invested and incubated by Viva BioInnovator (VBI) focusing on developing treatments for ocular diseases, announced positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201, a potent non-steroidal dual JAK1/TYK2 immunomodulator for the treatment of post-operative inflammation following cataract surgery.

VVN461 is a potent JAK1 immunomodulator independently developed by VivaVision, and there is increasing evidence showing that the JAK-STAT signaling pathway is essential for inflammation and immune response. VVN461 can inhibit multiple inflammatory cytokine pathways with high activity to treat postoperative inflammation of cataracts. The results of human pharmacokinetic studies showed that VVN461 ophthalmic solution had low exposure in plasma, indicating that VVN461 ophthalmic solution had a high safety profile due to low systemic toxicity while exerting local anti-inflammatory effects.

VIVA Linkedin

Portfolio Companies' Project Progress

Seraxis Announces FDA IND Allowance for Clinical Study of SR-02 Replacement Islets for Type 1 Diabetes

October 15, 2024, Seraxis Inc., a clinical stage regenerative medicine company invested and incubated by Viva BioInnovator (VBI), has received FDA's allowance of an Investigational New Drug (IND) application for a Phase I/II clinical study of its novel islet replacement therapy SR-02. SR-02 is the first reprogrammed stem cell-derived pancreatic product candidate allowed by FDA for testing in humans as a potential functional cure for insulin-requiring diabetes.

Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors

On September 16, 2024, Cybrexa Therapeutics which is co-invested and incubated by Viva BioInnovator (VBI) announced positive final results from its Phase 1 clinical trial of CBX-12 (alphalex™ exatecan). These data demonstrate that CBX-12 is well tolerated and exhibits promising activity across a range of advanced or metastatic solid tumors, including ovarian, breast, thymic, gall bladder, non-small cell lung cancer (NSCLC) and colorectal cancers, underscoring its potential as a highly differentiated conjugate with broad antitumor activity. The study results were presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024.

HAYA Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform

September 04, 2024--HAYA Therapeutics,SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA's advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners will identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions.

About Viva Biotech

Listing Date
B2019.05.09
Price (2024.12.31)
HKD 0.86
52 WK Range
HKD 0.41-1.20
Market Cap (2024.12.31)
HKD 1.83 Billion

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial drug delivery to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX-MS, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary Langhua Pharmaceutical, we offer worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva Biotech embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of June 30, 2024, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,350 biotech and pharmaceutical clients around the world. We have invested and incubated 92 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

Investor & Media Enquiries

Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact: Tel: 852-3150 6788
Email: ir@vivabiotech.com; VivaBiotech.hk@pordahavas.com